Swedish clinical-stage biotech company Oxcia AB, which develops therapies targeting oxidative stress and DNA damage response pathways, announced on Thursday that the European Medicines Agency has made the decision to grant Orphan Drug Designation for OXC-201 in idiopathic pulmonary fibrosis.
The designation provides regulatory and financial incentives, including 10 years of market exclusivity, scientific advice, support for clinical-trial design, substantial fee reductions and access to the Centralised Authorisation Procedure. It also increases eligibility for grants and accelerated regulatory pathways.
OXC-201 is being developed for idiopathic pulmonary fibrosis, a progressive disease characterised by lung scarring that restricts breathing and reduces oxygen supply, with median survival of three to five years. Preclinical data show effects on inflammatory and fibrotic markers, improved lung function and indications of reduced coughing, alongside evidence of good tolerability.
Clinical trials are scheduled to begin in 2027.
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study
argenx reports positive Phase 2 results for FB102 in coeliac disease
Mozart Therapeutics presents MTX-101 clinical and preclinical data at EASD Annual Meeting
Johnson & Johnson reports two-year ICOTYDE data showing sustained clearance in high-impact psoriasis
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
AFYREN ingredient enables global launch of natural propionic acid skincare product